Patrick O'Neil, EVP CLO & General Counsel of Ionis Pharmaceuticals Inc (NASDAQ:IONS), has sold 7,744 shares of the company on January 17, 2024, according to a recent SEC filing.
Ionis Pharmaceuticals Inc (NASDAQ:IONS), a leader in RNA-targeted drug discovery and development, has seen a recent insider transaction according to a SEC Filing.